Information Library
Clinical and marketing materials - Connect with investigators, regulators and physicians
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Patient Registries: A Taxonomy for the Design, Development and Implementation
June 25, 2009
Recommendations from the ISPOR Patient Registry Classification, Strategy & Design Working Group, Team 2, for developing standard language for the characterization, classification, strategy, design, and execution of patient registries to generate data for outcomes research purposes. -
Orphan Drugs in the U.S.
June 24, 2009
Presentation by Dr. John Doyle, Market Access Practice Leader, from ISPOR 14th Annual International Meeting 2009(International Society for Pharmacoeconomics and Outcomes Research) on “Orphan Drugs' Market Access in the U.S.” -
Early phase strategies
June 15, 2009
Web cast about Early Phase Strategies. -
QT Population Modeling and Simulation Case Study
June 15, 2009
The importance of determining the most strategic Phase I/IIa study conducted by leading specialists shouldn’t be understated. Gain insight into QT and Population Modeling & Simulation. -
The Importance of Latin America
June 8, 2009
Video showing why Latin America’s a great option for Clinical trials. With a total population over 500 million people and only two major languages, you will find a world of opportunity in the region. -
India Today: Quintiles Central Laboratory
June 8, 2009
Video explaining why India’s a great option for clinical trials. Benefits include access to patients, potential cost savings, experienced investigators, and state of the art technology. -
Oversight Group Management Services
April 16, 2009
Quintiles provides a high level of experience, expertise and customer service to the entire clinical trial process. This is especially true for the oversight group management service, known as CEVA. -
Risk Mitigation Programs
April 16, 2009
Risk mitigation measures can help keep valuable drugs on the market, even when their safety profile includes adverse events that might negatively affect the benefit risk balance. -
Risk Assessment & Strategy
April 16, 2009
Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile. -
Phase IIIb/IV Studies
April 16, 2009
New, more efficient delivery models help meet the increasing demands of Phase IIIB/IV Studies.